IVP · As filed with the SEC

Inspire Veterinary Partners income statement, by fiscal year

The statement as Inspire Veterinary Partners presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations · USD, except per-share amounts

USD, except per-share amounts	FY2024 Year ended Dec 31, 2024	FY2023 Year ended Dec 31, 2023
Total revenue	16,592,109	16,675,393
Service Revenue	12,188,526	11,879,934
Product Revenue	4,403,583	4,795,459
Operating expenses
Cost of Service Revenue	9,736,282	9,700,963
Cost of Product Revenue	3,563,279	3,420,515
General and administrative expenses	11,421,352	9,476,287
Depreciation and amortization	1,308,619	1,252,539
Impairment expense	56,664	—
Gain on sale of business	(467,049)	—
Total operating expenses	25,619,147	23,850,304
Loss from operations	(9,027,038)	(7,174,911)
Other income (expenses):
Interest income	53	21
Interest expense	(3,098,290)	(2,538,710)
Loss on debt extinguishment	—	(16,105)
Loss on debt modification	(2,134,218)	(927,054)
Beneficial conversion feature	—	(4,137,261)
Other income (expenses)	(4,768)	1,134
Total other expenses	(5,237,223)	(7,617,975)
Loss before income taxes	(14,264,261)	(14,792,886)
Net loss	(14,264,261)	(14,792,886)
Dividend on convertible series A preferred stock	(220,850)	(271,245)
Net loss attributable to class A and B common stockholders	(14,485,111)	(15,064,131)
Net loss per Class A and B common shares:
Class A and B Common Shares	(2.61)	(3.50)
Class A and B Common Shares	(2.61)	(3.50)
Weighted average shares outstanding per Class A and B common shares:
Class A and B Common Shares	5,550,959	4,309,796
Class A and B Common Shares	5,550,959	4,309,796

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.